**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | SGO DCU | **Project Code** | PI5VDU043 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

Friday, April 3

**Project Type**

Video (2)

Downloadable Slides

Podcast

**Email Blast Included?**

Yes

No

Subject Line: Daily Clinical Updates: Key Data From the 2015 Society of Gynecologic Oncology Annual Meeting

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

* Oncology Guru
* Shaping the Future of Personalized Therapy in Ovarian Cancer: A Focus on BRCA Biomarkers – Webcast & Downloadable Slides
* Next Steps in Optimizing Targeted Therapy of Ovarian Cancer: Exploring the Impact of *BRCA* Status – Downloadable Slides

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

[ortmannc@gene.com](mailto:ortmannc@gene.com)

[**marlana.henry@astrazeneca.com**](mailto:marlana.henry@astrazeneca.com)

**Slides**

Slides Included

Yes

No

**CME?**

Yes

No

Webcast/PDS URL:

**www.primeoncology.org/2015\_chicago\_ovarian\_dcu**

**Additional Components**

Cases with Voting

Polls- Pre-Posttest Questions for both videos

Video Segmentation

Table of Contents

Other:

**Mobile App Title: 2015 SGO DCU**

**Listing Page**

**[Insert small DCU Graphic to the left]**

**[TITLE]**

Daily Clinical Updates: Critical Analysis and Practical Application of Key Data From the 2015 Society of Gynecologic Oncology Annual Meeting - Expanded Therapeutic Options for Recurrent Ovarian Cancer

**[DATE** | **LOCATION]**

March 2015|Chicago, Illinois, United States

**Landing Page**

**[Insert DCU Graphic header]**

**LEFT SIDE**

**[Insert Text below]**

Daily Clinical Updates: Critical Analysis and Practical Application of Key Data From the 2015 Society of Gynecologic Oncology Annual Meeting - Expanded Therapeutic Options for Recurrent Ovarian Cancer

**Activity Features**

**[Insert icon]** Expert Discussion

**[Insert icon]** Downloadable Slides

**[Insert icon]** Podcast

**[Insert icon]** CME-Certified

**RIGHT SIDE**

**ACTIVITY OVERVIEW**

View CME-certified expert discussions regarding exciting news focusing on targeted agents for the treatment of ovarian cancer.

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**BOTTOM MIDDLE**

* Targeted therapy for ovarian cancer – antiangiogenic agents
* Targeted therapy for ovarian cancer – PARP inhibitors

**[Tab- Antiangiogenic agents]**

Antiangiogenic agents

Discussants: Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, Texas

Bradley J. Monk, MD,FACS, FACOG, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, Arizona

Featured Abstract:

**Abstract #3: A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)**

**[Button] View**

**[Tab-PARP inhibitors]**

PARP inhibitors

Discussants:

Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, Texas

Bradley J. Monk, MD,FACS, FACOG, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, Arizona

Featured Abstracts:

**Abstract #13: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a *BRCA* mutation: Overall survival adjusted for post-progression PARP inhibitor therapy**

**Abstract #14: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline *BRCA1/2* mutation: A multi-study sub-analysis**

**Abstract LBA: Tumor *BRCA* mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial**

**[Button] View**

**CME Information Pop-Up**

**Release Date**   
April 3, 2015  
  
**Expiration Date**   
April 3, 2016  
  
**Faculty**

**Robert L. Coleman, MD, FACOG, FACS**

**The University of Texas**

**MD Anderson Cancer Center**

**Houston, Texas**

**Bradley J. Monk, MD, FACS, FACOG**

**Creighton University School of Medicine**

**at St. Joseph’s Hospital and Medical Center**

**Phoenix, Arizona**

**Learning Objectives**  
After successful completion of this educational activity, participants should be able to:

* Evaluate recent data from national society meetings that have the potential to impact practice, including data related to PARP inhibitors and antiangiogenic agents in ovarian cancer
* Identify patients who would most likely benefit from referral to a clinical trial

**Provider**  
This activity is provided by prIME Oncology.

**Support**   
This educational activity is supported by grants from AstraZeneca and Genentech.

**Target Audience**   
This activity is specifically designed to meet the needs of medical, gynecologic, surgical, and radiation oncologists and other healthcare professionals involved in the treatment of patients with cancer.

**Continuing Medical Education**  
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credits****™****.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

* Antiangiogenic agents: XX
* PARP inhibitors: XX

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).   
  
Links to the posttests are available on the video player pages.

In order to claim credit for these activities, a score of XX% or higher is required on each test.

**Disclosure of Relevant Financial Relationships**  
prIME Oncology assesses relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

**Faculty Disclosures**  
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Coleman has \_\_\_\_\_\_\_. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Monk has disclosed that he has received consulting fees from Advaxis, Amgen, AstraZeneca, Cerulean, GlaxoSmithKline, Gradalis, Merck, Roche/Genentech, TESARO, and Verastem. He has also performed contracted research for Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Novartis, and TESARO. He has received fees for non-CME services from AstraZeneca and Roche/Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Amy Furedy, RN, OCN (clinical content reviewer/planner) – no relevant financial relationships
* Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

**Disclosure Regarding Unlabeled Use**  
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

**Player Page-Antiangiogenic agents**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons- Evaluate and Claim Credit]**

**Activity Information**

**ACTIVITY OVERVIEW**

**ACTIVITY OVERVIEW**

View CME-certified expert discussions regarding exciting news focusing on antiangiogenic agents for the treatment of ovarian cancer.

**FEATURED EXPERTS**

**Robert L. Coleman, MD, FACOG, FACS**

**The University of Texas MD Anderson Cancer Center**

**Houston, Texas**

**Bradley J. Monk, MD, FACS, FACOG**

**Creighton University School of Medicine**

**at St. Joseph’s Hospital and Medical Center**

**Phoenix, Arizona**

**FEATURED ABSTRACTS**

**Abstract #3: A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213)**

**SUPPORT STATEMENT**This educational activity is supported by grants from AstraZeneca and Genentech.

**Player Page-PARP inhibitors**

**[Insert DCU Graphic header]**

**[INSERT VIDEO]**

**[Buttons- Evaluate and Claim Credit]**

**Activity Information**

**ACTIVITY OVERVIEW**

**ACTIVITY OVERVIEW**

View CME-certified expert discussions regarding exciting news focusing on PARP inhibitors for the treatment of ovarian cancer.

**FEATURED EXPERTS**

**Robert L. Coleman, MD, FACOG, FACS**

**The University of Texas MD Anderson Cancer Center**

**Houston, Texas**

**Bradley J. Monk, MD, FACS, FACOG**

**Creighton University School of Medicine**

**at St. Joseph’s Hospital and Medical Center**

**Phoenix, Arizona**

**FEATURED ABSTRACTS**

**Abstract #13: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a *BRCA* mutation: Overall survival adjusted for post-progression PARP inhibitor therapy**

**Abstract #14: Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline *BRCA1/2* mutation: A multi-study sub-analysis**

**Abstract LBA: Tumor *BRCA* mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial**

**SUPPORT STATEMENT**This educational activity is supported by grants from AstraZeneca and Genentech.

**PODCAST**

Listing: Daily Clinical Updates: Critical Analysis and Practical Application of Key Data From the 2015 Society of Gynecologic Oncology Annual Meeting - Expanded Therapeutic Options for Recurrent Ovarian Cancer (Antiangiogenic Agents)

Description: Robert L. Coleman, MD, FACOG, FACS, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Bradley J. Monk, MD, FACS, FACOG, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, discuss the role of antiangiogenic agents for the treatment of ovarian cancer.

Listing: Daily Clinical Updates: Critical Analysis and Practical Application of Key From the 2015 Society of Gynecologic Oncology Annual Meeting - Expanded Therapeutic Options for Recurrent Ovarian Cancer (PARP Inhibitors)

Description:

Robert L. Coleman, MD, FACOG, FACS, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and, Bradley J. Monk, MD, FACS, FACOG, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, Arizona, discuss the use of PARP inhibitors for the treatment of ovarian cancer.